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Abstract 
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden 
healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial 
treatments. Approval of a biosimilar product relies on the demonstration of “comparability” or “no clinically meaningful 
differences” as compared to its reference biologic product. Biosimilar products for erythropoietin, granulocyte colony-
stimulating factor, trastuzumab, and rituximab are already available, and the regulatory processes in various countries 
are constantly evolving. It is important that oncologists be familiar with the potential issues surrounding the clinical 
use of biosimilar products. In this review article, we provide background information about biosimilar products and 
their regulatory approval processes, followed by a discussion of individual biosimilar drugs.
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Background
Biologic therapies, such as the monoclonal antibodies 
(mAbs) trastuzumab and bevacizumab, have prolonged 
the survival of cancer patients, but their high costs have 
also resulted in substantial financial burdens being placed 
on individual patients and on healthcare systems as a 
whole [1]. Because the patents of many biologic products 
in oncology are set to expire (Table  1), many biosimi-
lar products are being developed and will soon become 
available in global pharmaceutical markets. The lower 
costs of these biosimilar drugs compared with their ref-
erence biologics can help reduce cancer drug costs and 
potentially allow more patients to gain access to the 
drugs, thus improving patient outcomes.
“Biosimilar”, as the name implies, is a biologic that is 
similar to the licensed “reference” drug. Before a bio-
similar is incorporated into the clinical management of 
patients, clinicians should determine whether, based on 
efficacy and safety, the biosimilar can be used “instead 
of” or “interchangeably with” the reference biologic. 
Regulatory authorities play an important role in the 
development of biosimilars, and medical societies help 
guide clinicians on the use of biosimilars [2–5]. Currently 
available and of most interest in the field of oncology are 
biosimilars of the supportive agents filgrastim and eryth-
ropoietin and the mAbs trastuzumab and rituximab. Bev-
acizumab and cetuximab are innovator drugs in oncology 
whose patents will expire in the next few years [6]. Recent 
surveys conducted in America, Europe, and Asia showed 
that most clinicians are not very familiar with biosimi-
lars [5, 7, 8]. In this review, we provide information that 
oncologists need to know about this new category of 
medicine.
What is a biosimilar?
“Biosimilar” [3, 4], “similar biotherapeutic product” 
[2], “follow-on biologic” [9], and “subsequent entry bio-
logic” [10] are terms for a successor drug that has the 
same mechanism of action as the original biologic. The 
World Health Organization (WHO) defines biosimilar 
as “a biotherapeutic product which is similar in terms of 
quality, safety, and efficacy to an already licensed refer-
ence biotherapeutic product” [2]. Unlike simple generic 
medicines that are chemically synthesized, biologics are 
produced by a more complex manufacturing process, 
are derived from living cells or organisms, and consist of 
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relatively large and complex molecules [11]. Any varia-
tions in the manufacturing condition can result in altera-
tions in biological function, causing changes in efficacy; 
and/or induce an immune response (immunogenicity), 
leading to a new adverse reaction. There is certain degree 
of variability in the manufacturing process of biologics 
that exists even between different batches of the same 
product. The expiration of a biologic’s patent unveils only 
the primary amino sequence and the structure of the 
drug, not precise production information. The attempted 
replica can be considered only highly similar to the origi-
nal biologic, not truly “generic.” Therefore, the criteria 
for obtaining regulatory approval of chemically derived 
generic drugs are inappropriate for biosimilars. Table  2 
summarizes the differences between biosimilars and 
generic drugs.
Biosimilar regulatory approval
The European Medicines Agency (EMA) is the body 
responsible for approving biosimilars in the European 
Union (EU), and it established the first legislative path-
way for doing so. In 2005, it published guidelines gov-
erning the development of biosimilars; since then, it has 
developed individual guidelines for the biosimilars of 
granulocyte colony-stimulating factor (G-CSF), eryth-
ropoietin, and various mAbs [3]. The EMA defines bio-
similars as “a biological medicinal product that contains 
a version of the active substance of an already authorized 
reference medicinal product and similarity to the refer-
ence product in terms of quality characteristics, biologi-
cal activity, safety and efficacy based on a comprehensive 
comparability exercise needs to be established” [3]. The 
concept of “comparability” in reference to the original 
biologic is considered fundamental to the approval of a 
biosimilar. Comprehensive comparability studies should 
demonstrate similarity in physiochemical, biological, and 
immunological characteristics and in efficacy and safety. 
Immunogenicity has been a safety concern for biosimi-
lars; thus, a robust pharmacovigilance system and risk 
management procedures should be in place to ensure 
long-term safety.
In the EU, the first biosimilar product was approved in 
2006 [12]. Many countries soon followed the EMA’s lead. 
Since 2008, Australia has followed the EU guidelines and 
approved its first biosimilar in 2010 [13]. In 2013, the 
Australia’s Therapeutic Goods Administration released 
a guidance document on the evaluation of biosimilars 
[14]. Canada also follows the EU regulatory process and 
finalized its guidelines in 2010 [10]. In 2009, the WHO 
formalized guidelines on the evaluation of similar bio-
therapeutic products [2]. The United States of America 
(USA) has lagged behind in the development of biosim-
ilars, having approved its first biosimilar only in March 
2015 [9]. The United States Food and Drug Administra-
tion (US FDA) issued final guidelines in April 2015 [4]. It 
defines biosimilar as “a biological product that is highly 
similar to the reference product notwithstanding minor 
differences in clinically inactive components and that 
there are no clinically meaningful differences between 
the biological product and the reference product in terms 
of safety, purity and potency.” Emerging drug markets of 
Asia are typically generics driven; they offer an attractive 
market for the developers of biosimilars, but regulations 
vary across countries, and not every country has issued 
guidelines [15–21] (Table  3). Some Asian countries fol-
low a specific biosimilar pathway that is akin to the EMA 
model [16–19, 22]. Singapore has approved biosimilar 
products only if they have been approved by other agen-
cies namely, the EMA, the US FDA, the Australian Ther-
apeutic Goods Administration, or the Health Canada 
Table 1 Key oncological biologics whose patents either have expired or will expire soon
Biologic (brand name) Manufacturer Estimated patent expiry (month and year)
United States Europe
Supportive agents
Filgrastim (Neupogen) Amgen/Roche/Jassen Expired Expired
Pegfilgrastim (Neulasta) Amgen Expired Aug 2017
Epoetin alfa (Emprex/Epogen/Procrit) Amgen/Jassen Expired Expired
Darbepoetin alfa (Aranesp) Amgen May 2024 Jul 2016
Monoclonal antibodies
Trastuzumab (Herceptin) Genentech/Roche Jun 2019 Expired
Rituximab (Rituxan/MabThera) Roche Sep 2016 Expired
Cetuximab (Erbitux) Eli Lilly/Bristol-Myers
Squibb/Merck KgaA
Expired Expired
Bevacizumab (Avastin) Genentech/Roche Jul 2019 Jan 2022
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[19]. In India, less stringent regulatory requirements 
have led to many biosimilars being available in the mar-
ket since 2000; however, not until 2012 were guidelines 
issued [21]. In China, specific guidelines to be developed 
by the China Food and Drug Administration are pend-
ing; currently, the approval of biosimilars follows a sim-
plified new product approval pathway [20]. Worldwide, 
regulations are evolving, and global harmonization of 
regulatory standards would definitely help manufacturers 
develop biosimilars in a more cost-effective way [23].
Overall, the USA and the EU have similar basic prin-
ciples in terms of quality and clinical and non-clinical 
comparability testing strategies [3, 4]. A single reference 
product as comparator should be used throughout the 
studies to enable the generation of coherent data and con-
clusions. The dosage and the form and route of adminis-
tration of the biosimilar and the reference biologic should 
be the same. The totality-of-the-evidence approach is 
adopted to review the marketing authorization applica-
tion of biosimilar products, and a stepwise approach for 
demonstrating biosimilarity is recommended (Fig. 1). At 
each step, the biosimilar developer should evaluate and 
justify any identified uncertainties or differences between 
the biosimilar and the reference biologic and maintain 
an active dialogue with the approval agency, all of which 
affect the type and amount of data required to move on 
to the next step. Demonstrating high molecular similar-
ity between the biosimilar and the reference biologic at 
the beginning reduces the amount of preclinical and 
clinical data that are subsequently required. If the refer-
ence biologic is licensed for more than one indication, 
similarity of the biosimilar should be demonstrated sepa-
rately for each indication. Extrapolation of efficacy and 
safety data from one therapeutic indication to another is 
allowed, provided that there is evidence that the mecha-
nisms of action and safety in the subpopulations evalu-
ated are very likely to be equivalent. Currently, the EMA 
and the US FDA are collaborating to facilitate the global 
development of biosimilars. Regular meetings are being 
held between the two agencies to exchange informa-
tion on the development of biosimilar products and on 
pharmacovigilance.
Pharmacovigilance of biosimilars
Pharmacovigilance is “the science and activities relating 
to the detection, assessment, understand and prevention 
of adverse effects or any other drug related problem” [24]. 
Pharmacovigilance is particularly important when deal-
ing with biologics because safety data from pre-authori-
zation clinical studies only identify some potential risks 
and are insufficient to detect rare adverse events. Immu-
nogenicity can be related to the route of administration, 
dosing regimen, patient-related factors, and disease-
related factors, and it is an ongoing safety concern [3]. 
The case of erythropoietin antibody-mediated pure red 
cell aplasia (PRCA) is a good example of immunogenic-
ity being identified by post-marketing surveillance, when 
a small change in the formulation of the biologic led to 
Table 2 Comparisons between biosimilars and generics
US the United States; FDA the Food and Drug Administration; EU the European Union; EMA the European Medicines Agency
Feature Biosimilars Generics
Definitions US FDA A biosimilar is a biological product that is highly similar 
to a licensed reference biological product notwithstanding 
minor differences in clinically inactive components; and there 
are no clinically meaningful differences between the biologi-
cal product and the reference product in terms of the safety, 
purity, and potency of the product
US FDA A generic drug is identical to a brand name 
drug in dosage, safety, strength, route of administra-
tion, quality, performance, and intended use
EU EMA A biosimilar is a biological medicinal product that con-
tains a version of the active substance of an already authorized 
original biological medicinal product (reference medicinal 
product). Similarity to the reference medicinal product in 
terms of quality characteristics, biological activity, safety, and 
efficacy based on a comprehensive comparability exercise 
need to be established
EU EMA A generic medicine is a medicine that is devel-
oped to be the same as a medicine that has already 
been authorized (the “reference medicine”). It contains 
the same active substance(s) as the reference medi-
cine, and it is used at the same dose(s) to treat the 
same disease(s) as the reference medicine
Manufacturing processes Complex, as they are derived from living cells or organisms, 
sensitive to manufacturing changes
Simple, as produced by chemical synthesis
Immunogenicity Immunogenic Mostly non-immunogenic
Compared with original 
counterparts
Similar but not identical
Need to demonstrate comparability (i.e., no clinically meaningful 
differences) to its comparator (the reference drug)
Automatic substitution not recommended (some biosimilars 
might not carry all the same indications, especially if the refer-
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an adverse immune response [25]. In addition to immu-
nogenicity, other safety concerns, such as the adminis-
tration of hematopoietic colony-stimulating factors to 
healthy donors, which led to the development of hema-
tologic malignancies, have been observed with biologics 
[26]. To ensure long-term safety, biosimilars are required 
to follow the same pharmacovigilance regulations as their 
reference counterparts. Required as part of the market-
ing application are a risk management plan describing 
the safety profile of the drug as well as proposed phar-
macovigilance and risk minimization measures. After 
biosimilars are approved, companies are required to sub-
mit periodic safety reports. Prescribers should report any 
suspected serious adverse reactions associated with the 
use of biosimilars, and ensuring traceability of the bio-
similars associated with adverse events is essential. To 
date, no specific safety concerns regarding approved and 
marketed biosimilars have been identified.
Interchangeability between a biologic and its biosimilar
Generic medications can be used interchangeably with 
their branded originators since they are considered ther-
apeutically equivalent; often, pharmacists may substitute 
a prescribed drug for a generic medication without the 
prior consent of the treating physician (known as “auto-
matic substitution”) [23]. Interchangeability refers to 
switching back and forth between two medicinal prod-
ucts without any observed changes in efficacy or safety 
risk. Biosimilarity does not imply interchangeability, and 
interchangeability does not always imply substitutability.
Some biosimilars might not have all the same indica-
tions that the reference biologics are approved for, espe-
cially if the reference biologics have multiple mechanisms 
of action. Even if a biosimilar is approved for the same 
indication as the reference originator, it is generally rec-
ommended that automatic substitution not be allowed 
because the clinician should be fully aware of which drug 
Table 3 Global regulations for the evaluation and approval of biosimilars
EU the European Union; EMA the European Medicines Agency; TGA the Therapeutic Goods Administration; CDE the Center for Drug Evaluation; NPCB the National 
Pharmaceutical Control Bureau; HSA the Health Sciences Authority; PMDA the Pharmaceuticals and Medical Devices Agency; MFDS the Ministry of Food and Drug 
Safety; US the United States; FDA the Food and Drug Administration; Medsafe the Medical Devices Safety Authority; CFDA the China Food and Drug Administration
Feature Yes No








India—Ministry of Science and Technology and 
Ministry of Health and Family Welfare, 2012
New Zealand—Medsafe (but refers to both EU and US 
guidelines)
China—CFDA (follows a simplified new product 
approval pathway)
Reference product must be regis-









Malaysia (products registered in the reference countries 
Australia, Canada, EU, United Kingdom, France, Japan, 
Sweden, Switzerland, and US are considered accept-
able) 
Interchangeability designation? US
Singapore and Malaysia (allow if both biosimilar and 
reference product approved for the same indica-
tion but cannot be substituted with one another 

















India (allow for extrapolation of therapeutic similarity 
across indications in certain cases, depending on 
clinical experience, available literature data, and 
whether the same mechanisms of action or the 
same receptor(s) are involved in all indications)
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is given to the patient. If, during a treatment period, 
alternation or switching between the biosimilar and 
the branded biologic cannot be avoided, this must be 
recorded accurately; maintaining pharmacovigilance by 
clearly delineating between biosimilars and branded orig-
inators is important.
The USA allows an “interchangeable” designation for 
biosimilars, provided that, in any given patient, the bio-
similar can be expected to produce the same clinical 
results as the reference product and that the safety and 
efficacy observed when alternating or switching between 
the two remain the same [4]. Other countries, such as 
Australia and Canada, do not provide recommendations 
on whether a biosimilar can be used interchangeably with 
its reference medicine, and they have officially prohibited 
the automatic substitution of biologics [10, 14]. The EMA 
also does not provide an interchangeable recommen-
dation when approving a biosimilar [3]. Individual EU 
countries must decide on the interchangeability between 
a biologic and its biosimilar [27].
Biosimilar epoetins
Erythropoiesis-stimulating agents (ESAs), such as epo-
etin alfa (Eprex, Erypro), epoetin beta (NeoRecormon), 
and darbepoetin alfa (Aranesp), are approved for can-
cer patients with chemotherapy-induced anemia [28, 
29]. They are considered equivalent in terms of efficacy 
and safety. In 2010, concerns about an increased risk of 
venous thromboembolism and an increased mortality 
risk associated with the use of ESAs by cancer patients 
led the European Society for Medical Oncology and the 
American Society of Clinical Oncology/American Soci-
ety of Hematology to issue revised guidelines [29]. These 
guidelines recommended against the use of ESAs for the 
treatment of malignancy-associated anemia in patients 
not receiving concurrent myelosuppressive chemother-
apy; they also recommended against the use of ESAs 
for patients receiving chemotherapy for curative intent, 
until further safety data are collected. However, the 
EMA’s Committee for Medicinal Products for Human 
Use stated that the benefits of using ESAs for approved 
indications (hemoglobin target range of 10–12  g/dL in 
chemotherapy-induced anemia) continue to outweigh 
the associated risks, including increased risk of tumor 
progression and venous thromboembolism and reduced 
survival, except for those cancer patients with a reason-
ably long life expectancy whose anemia should be treated 
by blood transfusions [30].
In 2007, two biosimilar epoetins–epoetin alfa, mar-
keted as Binocrit, Abseamed, and Epoetin Alfa Hexal; 
and epoetin zeta, marketed as Retacrit and Silapo were 
approved in Europe [31–35] (Table  4). Comparability 
of these biosimilar epoetins with their reference drugs 
Eprex and Erypo was demonstrated in the setting of 
renal anemia [36]. Their use in the treatment of chemo-
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Fig. 1 Stepwise approach to demonstrating biosimilarity between biosimilars and reference biologics
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because, based on the extrapolation of data, the mecha-
nisms of action for epoetins are the same for all approved 
indications. PRCA caused by cross-reacting neutralizing 
antibodies against erythropoietin is a rare but known 
serious adverse event that has been observed with the use 
of erythropoietin in patients with chronic renal failure 
[37]. Therefore, the post-marketing and risk management 
plans of biosimilar epoetins particularly focus on PRCA.
Biosimilar G‑CSF
G-CSF is widely used in the field of oncology [38]. It is 
used to decrease the incidence of chemotherapy-related 
febrile neutropenia, facilitate dose-intensity chemother-
apy, and mobilize hematopoietic stem cells for collection. 
Currently, there are eight EMA-licensed filgrastim bio-
similars, the first of which was licensed in Europe in 2008 
[39–46]. These G-CSF biosimilars were approved by the 
EMA for all the registered indications of the reference 
drug Neupogen, based on their comparable efficacy and 
safety profiles in the treatment of chemotherapy-induced 
neutropenia [47–51] (Table  5). In March 2015, the US 
FDA approved its first biosimilar product Zarxio (fil-
grastim-sndz), which has all the same indications as the 
reference drug Neupogen [52]. Key studies showing the 
comparability in efficacy and safety of the biosimilar fil-
grastim to its reference drug are summarized in Table 6.
Enhanced by a 20-kDa polyethylene glycol molecule 
compared with filgrastim, pegfilgrastim has a longer half-
life and is administered less frequently [53]. Pegfilgrastim 
has been approved by the US FDA and the EMA since 
2002 and is indicated in non-myeloid cancer patients 
undergoing chemotherapy to decrease the incidence 
of febrile neutropenia [54, 55]. Unlike filgrastim, pegfil-
grastim is not approved for hematopoietic progenitor cell 
mobilization. Since 2007, four pegfilgrastim biosimilars 
have been approved in India [56]. In December 2014, 
Apotex, in conjunction with Intas Pharmaceuticals, suc-
cessfully filed its biosimilar pegylated apofilgrastim 
with the US FDA. Another biosimilar pegfilgrastim, 
LA-EP2006, developed by Sandoz, is being compared 
with its reference product Neulasta in three phase III 
studies; the results will be used to support the company’s 
registration application in the USA and the EU. The US 
patent for pegfilgrastim expired in October 2015; the EU 
patent is expected to expire in August 2017.
Biosimilar trastuzumab
Trastuzumab is a humanized mAb that targets human 
epidermal growth factor receptor 2 (HER2). For patients 
with HER2-positive breast cancer, it is the standard of 
care in the neoadjuvant, adjuvant, and palliative settings 
[57, 58]. It is also indicated for the palliative treatment 
of HER2-positive gastric cancer. Biosimilar trastuzumab 
is the first biosimilar mAb available for the treatment of 
cancer (Table  7). In November 2013, the trastuzumab 
biosimilar Hertraz was launched in India after approval 
was granted by the Drug Controller General of India 
[59]. In January 2014, the South Korean Ministry of Food 
and Drug Safety approved the trastuzumab biosimilar 
CT-P6 (Herzuma) based on the results of global clini-
cal trials involving 558 patients in 18 countries and 115 
sites [60]. In January 2016, the Ministry of Health of the 
Russian Federation approved the trastuzumab biosimilar 
HERtiCAD based on the results of a randomized, mul-
ticenter clinical study (NCT01764022) comparing the 
pharmacokinetics, immunogenicity, safety, and efficacy 
of BCD-022 with those of the reference drug Herceptin, 
both in combination with paclitaxel in treating patients 
with metastatic breast cancer [61]. The study demon-
strated the non-inferiority of BCD-022 compared with 
Table 4 List of currently approved erythropoietin biosimilars
Region Active substance  
(laboratory code)
Brand name  
(pharmaceutical company)
Indications in oncology Approval date
Europe Epoetin alfa (HX575) Binocrit (Sandoz) Treatment of anemia and reduction of transfu-
sion requirements in adult patients receiving 
chemotherapy for solid tumors, malignant 
lymphoma, or multiple myeloma, and at risk 
of transfusion as assessed by the patient’s 
general status (e.g., cardiovascular status, pre-
existing anemia at the start of chemotherapy)
28/08/2007
Abseamed (Medice Arzneimittel) 28/08/2007
Epoetin alfa Hexal (Hexal) 28/08/2007
Epoetin zeta (SB309) Retacrit (Hospira) 18/12/2007
Silapo (Stada Arzneimittel) 18/12/2007
Australia Epoetin lambda Aczicrit (Sandoz/Novartis) Treatment of anemia in patients with non-
myeloid malignancies where anemia develops 
as a result of concomitantly administered 





New Zealand Epoetin alpha (HX575) Binocrit (Novartis) Treatment of anemia in patients with non-
myeloid malignancies where anemia is due 
to the effect of concomitantly administered 
chemotherapy
27/02/2013
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Table 5 List of currently approved granulocyte colony-stimulating factor biosimilars
Region Active  
substance
Brand name  
(pharmaceutical company)
Indications in oncology Approval date
Europe Filgrastim-XM02 Ratiograstim (Ratiopharm) Reduction in the duration of chemotherapy-induced neutro-
penia and the incidence of febrile neutropenia (except for 
chronic myeloid leukemia and myelodysplastic syndromes)
Reduction in the duration of neutropenia caused by myeloabla-
tive therapy followed by bone marrow transplant




Filgrastim-EP2006 Filgrastim Hexal (Hexal) 06/02/2009
Zarzio (Sandoz) 06/02/2009
Filgrastim-PLD108 Nivestim (Hospira) 08/06/2010
Apo-Filgrastim Grastofil (Apotex) 18/10/2013
Accofil (Accord) 18/09/2014
United States Filgrastim-EP2006 Zarxio/(Sandoz) [Placeholder 
non-proprietary name: 
filgrastim-sndz]
Decrease in the incidence of infection, as manifested by febrile 
neutropenia, in patients with non-myeloid malignancies 
receiving myelosuppressive anti-cancer drugs associated with 
a significant incidence of severe neutropenia with fever
Reduction in the time to neutrophil recovery and the duration 
of fever, following induction or consolidation chemotherapy 
treatment of patients with acute myeloid leukemia
Reduction in the duration of neutropenia and neutropenia 
related clinical sequelae (e.g., febrile neutropenia) in patients 
with non-myeloid malignancies undergoing myeloablative 
chemotherapy followed by bone marrow transplantation
Mobilization of autologous hematopoietic progenitor cells into 
the peripheral blood for collection by leukapheresis
06/03/2015
Australia Filgrastim-PLD108 Nivestim (Hospira) Decrease in the incidence of infection, as manifested by febrile 
neutropenia, in patients with non-myeloid malignancies 
receiving myelosuppressive anti-cancer drugs in doses not 
usually requiring bone marrow transplantation;
Reduction in duration of neutropenia and clinical sequelae in 
patients undergoing induction and consolidation chemo-
therapy for acute myeloid leukemia;
Mobilization of autologous peripheral blood progenitor cells 
alone, or following myelosuppressive chemotherapy, to accel-
erate neutrophil and platelet recovery by infusion of such cells 
after myeloablative or myelosuppressive therapy in patients 
with non-myeloid malignancies;
Mobilization of peripheral blood progenitor cells in normal 
volunteers; for use in allogeneic peripheral blood progenitor 
cell transplantation;
Treatment of patients receiving myeloablative chemotherapy, 
for reducing the duration of neutropenia and clinical sequelae 
following autologous or allogeneic bone marrow transplanta-
tion
16/09/2010
Filgrastim-XM02 Tevagrastim (Aspen Pharmac-
are)
29/08/2011
Filgrastim-EP2006 Zarzio (Sandoz) 07/05/2013
New Zealand Filgrastim-PLD108 Nivestim (Hospira) Mobilization of autologous peripheral blood progenitor cells 
alone, or following myelosuppressive chemotherapy and the 
mobilization of peripheral blood progenitor cells in normal 
donors [allogeneic peripheral blood progenitor cell (PBPC)]
Reduction in the duration of neutropenia and the incidence 
of febrile neutropenia in patients treated with established 
cytotoxic chemotherapy for malignancy (with the exception 
of chronic myeloid leukemia and myelodysplastic syndromes) 
and for the reduction in the duration of neutropenia and its 
clinical sequelae in patients undergoing myeloablative therapy 
followed by bone marrow transplantation considered to be at 
increased risk of prolonged severe neutropenia
24/05/2012
Filgrastim-EP2006 Zarzio (Novartis) 31/03/2014
Singapore Filgrastim-PLD108 Nivestim (Hospira) Reduction in the duration of neutropenia and the incidence 
of febrile neutropenia in patients treated with established 
cytotoxic chemotherapy for malignancy (with the exception of 
chronic myeloid leukemia and myelodysplastic syndromes)
Reduction in the duration of neutropenia in patients undergo-
ing myeloablative therapy followed by bone marrow trans-
plantation considered to be at increased risk of prolonged 
severe neutropenia
17/07/2012
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Herceptin in terms of efficacy and safety. The primary 
patent on Herceptin in Europe expired in July 2014. Bio-
similar trastuzumab has not yet been approved in the EU, 
but several are in phase III development.
Biosimilar rituximab
Rituximab is an mAb that acts against CD20 to treat 
non-Hodgkin’s lymphoma (NHL) and chronic lym-
phocytic leukemia. Marketed by Roche as Rituxan and 
MabThera, rituximab was originally approved for use 
in 1997 in the USA [62] and in 1998 in the EU [63]. 
In November 2013, the patent for rituximab expired in 
the EU; in September 2016, it will expire in the USA. 
In 2007, Dr. Reddy’s Laboratories marketed Reditux 
in India as a biosimilar of rituximab to treat diffuse 
large B cell lymphoma [64]. However, Reditux is not a 
true biosimilar because it has not been studied head to 
head against its reference product. In May 2014, Bio-
cad’s Acellbia (also known as BCD020), a biosimilar of 
rituximab, was approved in Russia for the treatment 
of NHL [65] (Table 6). The approval was based on the 
results of a randomized, open-labelled study, involving 
over 30 centers in Ukraine, Russia, and India, which 
showed that the drug’s pharmacokinetics, pharmaco-
dynamics, efficacy, and safety were similar to rituxi-
mab [66].
Table 5 continued
Region Active  
substance
Brand name  
(pharmaceutical company)
Indications in oncology Approval date
Japan Filgrastim Filgrastim BS (Mochida/Fuji) Treatment in neutropenia induced by anti-cancer chemotherapy 21/11/2012
Filgrastim BS (Nippon Kayaku/
Teva)
28/02/2013
Filgrastim BS (Sandoz) 24/03/2014
Table 6 Key studies of biosimilar filgrastim that demonstrated clinical equivalence to the reference drug
PK pharmacokinetics; PD pharmacodynamics
Active substance Brand name Key studies of biosimilar filgrastim demonstrating clinical equivalence to reference 
drug
Filgrastim-XM02 Ratiograstim/Tevagrastim/Biograstim Multinational, multicenter, randomized, controlled phase III study; breast cancer patients 
receiving docetaxel/doxorubicin chemotherapy (n = 348)
Reference drug, Neupogen [47]
Multinational, multicenter, randomized, controlled phase III study; lung cancer patients 
receiving platinum based chemotherapy (n = 240)
Reference drug, Neupogen [48]
Multinational, multicenter, randomized, controlled phase III study; patients with non-Hodg-
kin lymphoma receiving chemotherapy (n = 92)
Reference drug, Neupogen [49]
Filgrastim-EP2006 Filgrastim Hexal/Zarzio Multinational, multicenter, randomized, controlled phase III study in chemo-naïve breast 
cancer patients receiving neoadjuvant/adjuvant docetaxel, doxorubicin, and cyclophos-
phamide chemotherapy (n = 218)
Reference product, Neupogen [50]
Filgrastim-PLD108 Nivestim Multicenter, randomized, controlled phase III study; breast cancer patients treated with 
doxorubicin and docetaxel in neoadjuvant/adjuvant or first-line metastatic setting 
(n = 279)
Reference drug, Neupogen [51]
Table 7 List of currently approved biosimilar monoclonal antibodies in oncology
HER2 human epidermal growth factor receptor 2
Region Active substance Brand name (pharmaceutical company) Approved indications in oncology Approval date
India Trastuzumab CANmab (Biocon)/Hertraz (Mylan) HER2-positive breast cancer 25/11/2013
South Korea Trastuzumab Herzuma (Celltrion) HER2-positive breast cancer
Advanced (metastatic) gastric cancer
15/01/2014
Russia Trastuzumab HERtiCAD (Biocad) Breast cancer 20/01/2016
Russia Rituximab AcellBia (CSJC biocad) CD20-positive non-Hodgkin’s B-cell lymphoma 25/05/2014
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Conclusions
The rationale for the development of biosimilar products 
is to improve patient access to biological therapies in a 
safe and cost-effective way. As the technology advances 
and evolves, so too do regulations governing the devel-
opment of biosimilars. Oncologists should be aware that 
biosimilars are not generics of biological medicines, but 
they do have comparable efficacy and safety to the origi-
nators. Pharmacovigilance is critical to ensuring the 
long-term quality and safety of biosimilars. With biosimi-
lars, it is important to be mindful of concerns about drug 
substitutions and extrapolation across indications.
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